SPE-LC/MS Bioanalytical Quantification Of The Biotherapeutic Peptide, Semaglutide From Plasma

By Mary Trudeau and Angela Scumaci, Waters Corporation

The following application note presents a comprehensive and highly refined approach to the bioanalytical quantification of the peptide therapeutic semaglutide in plasma, utilizing liquid chromatography-mass spectrometry (LC-MS). This method is characterized by its sensitivity, selectivity, and robustness to ensure reliable detection and measurement of semaglutide in complex biological matrices. The workflow integrates a selective solid-phase extraction (SPE) technique using the µElution™ 96-well format, which enhances sample preparation efficiency and minimizes sample loss. To further mitigate the common issue of peptide non-specific binding, the analysis employs QuanRecovery™ 96-well plates with MaxPeak™ High Performance Surfaces, which are specifically engineered to preserve peptide integrity throughout the analytical process. For chromatographic separation and detection, the method utilizes the ACQUITY™ UPLC™ Peptide CSH™ C18 Column in conjunction with the ACQUITY UPLC I-Class Plus System, which provides high-resolution separation and reproducibility.

Explore how these technologies enable fast, accurate, and reproducible quantification of semaglutide from plasma samples, which makes this method highly suitable for pharmacokinetic and bioavailability studies in both preclinical and clinical research settings.